EA202193211A1 - Лечение синуклеопатий - Google Patents

Лечение синуклеопатий

Info

Publication number
EA202193211A1
EA202193211A1 EA202193211A EA202193211A EA202193211A1 EA 202193211 A1 EA202193211 A1 EA 202193211A1 EA 202193211 A EA202193211 A EA 202193211A EA 202193211 A EA202193211 A EA 202193211A EA 202193211 A1 EA202193211 A1 EA 202193211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
synucleopathies
treatment
synucleopathy
administering
treating
Prior art date
Application number
EA202193211A
Other languages
English (en)
Inventor
Нитин Кришнаджи Дамле
Эндрю Майкл Голдфайн
Санджайкумар Нандлал Мандхане
Original Assignee
Сан Фарма Эдванст Рисерч Компани Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сан Фарма Эдванст Рисерч Компани Лтд. filed Critical Сан Фарма Эдванст Рисерч Компани Лтд.
Publication of EA202193211A1 publication Critical patent/EA202193211A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Способ лечения или предупреждения синуклеопатий у субъекта-человека, включающий введение терапевтически эффективного количества соединения формулы 1или его фармацевтически приемлемой соли.
EA202193211A 2019-06-11 2020-06-09 Лечение синуклеопатий EA202193211A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921023164 2019-06-11
PCT/IB2020/055425 WO2020250133A1 (en) 2019-06-11 2020-06-09 Treatment for synucleinopathies

Publications (1)

Publication Number Publication Date
EA202193211A1 true EA202193211A1 (ru) 2022-03-30

Family

ID=71094647

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193211A EA202193211A1 (ru) 2019-06-11 2020-06-09 Лечение синуклеопатий

Country Status (14)

Country Link
US (1) US20220257582A1 (ru)
EP (1) EP3982964A1 (ru)
JP (1) JP2022536331A (ru)
KR (1) KR20220024463A (ru)
CN (1) CN114040763A (ru)
AU (1) AU2020292703A1 (ru)
BR (1) BR112021024835A2 (ru)
CA (1) CA3142899A1 (ru)
CL (1) CL2021003303A1 (ru)
EA (1) EA202193211A1 (ru)
IL (1) IL288797A (ru)
MA (1) MA56179A (ru)
MX (1) MX2021015390A (ru)
WO (1) WO2020250133A1 (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214314A1 (en) 2022-05-02 2023-11-09 Sun Pharma Advanced Research Company Limited Vodobatinib for reducing progression of parkinson's disease

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003206397B2 (en) 2002-01-04 2008-07-17 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
CA2479257A1 (en) 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
TWI343806B (en) 2003-07-01 2011-06-21 Nat Health Research Institutes Methods of inhibiting neurodegenerative disease
US8618063B2 (en) 2008-04-09 2013-12-31 The Board Of Trustees Of The University Of Illinois Method for treating a synucleinopathy
WO2012098416A1 (en) 2011-01-21 2012-07-26 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
KR20140022063A (ko) 2011-04-07 2014-02-21 어리어드 파마슈티칼스, 인코포레이티드 신경 변성 질환을 치료하기 위한 방법 및 조성물
AU2013256227B2 (en) * 2012-05-02 2017-06-15 Georgetown University Treating neural disease with tyrosine kinase inhibitors
LT3463351T (lt) 2016-06-02 2022-06-10 Sun Pharma Advanced Research Company Limited Parkinsono ligos gydymas

Also Published As

Publication number Publication date
US20220257582A1 (en) 2022-08-18
MX2021015390A (es) 2022-01-24
CL2021003303A1 (es) 2022-08-19
BR112021024835A2 (pt) 2022-01-18
AU2020292703A1 (en) 2022-01-27
MA56179A (fr) 2022-04-20
JP2022536331A (ja) 2022-08-15
EP3982964A1 (en) 2022-04-20
CA3142899A1 (en) 2020-12-17
IL288797A (en) 2022-02-01
KR20220024463A (ko) 2022-03-03
WO2020250133A1 (en) 2020-12-17
CN114040763A (zh) 2022-02-11

Similar Documents

Publication Publication Date Title
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
PH12020551597A1 (en) Treatment of hidradenitis suppurativa using jak inhibitors
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
EA202090604A1 (ru) Хроманмонобактамовые соединения для лечения бактериальных инфекций
WO2020033838A3 (en) Treatment of egfr-mutant cancer
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
PH12021550713A1 (en) Medicament for the treatment of chronic cough
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
AR119159A1 (es) Tratamientos de angioedema
MX2020010417A (es) Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret.
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
NZ757711A (en) Antimicrobial compounds, compositions, and uses thereof
MX2022007911A (es) Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7.
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2022000143A (es) Metodos novedosos.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
WO2020128614A8 (en) Method for treating interstital lung disease
EA202193211A1 (ru) Лечение синуклеопатий
EA202193007A1 (ru) Соединения пирролидина
MX2019004200A (es) Terapia de combinacion.
MX2022003845A (es) Tratamientos cognitivos medicinales.
EA202193276A1 (ru) Способы лечения холангиокарциномы